Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immune system desensitization to peanut protein aims to reduce hypersensitivity in individuals with peanut allergy. It involves gradually increasing doses of peanut protein to raise the reaction threshold and mitigate risks from accidental exposure. Key allergens include Ara h 1, Ara h 2, and Ara h 6. Desensitization shifts the immune response towards tolerance, increasing protective antibodies and regulatory cells while decreasing allergy-driving factors. Treatment requires medical supervision due to the risk of allergic reactions.
Oral immunotherapy induces desensitization by modulating the immune response through repeated exposure to peanut protein, increasing IgG4, decreasing IgE, and expanding regulatory T cell populations.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peanut Allergenic Proteins (Immune Response) (Peanut Allergy Response).